Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 3.6% – What’s Next?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) were down 3.6% during trading on Wednesday . The stock traded as low as $15.00 and last traded at $15.05. Approximately 157,665 shares traded hands during trading, an increase of 107% from the average daily volume of 76,094 shares. The stock had previously closed at $15.61.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Coeptis Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Coeptis Therapeutics currently has a consensus rating of “Sell”.

Coeptis Therapeutics Trading Down 3.6%

The firm has a market cap of $80.37 million, a P/E ratio of -5.26 and a beta of -0.53. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.21 and a current ratio of 2.21. The firm has a fifty day moving average of $15.78 and a 200-day moving average of $12.76.

Coeptis Therapeutics (NASDAQ:COEP) last issued its earnings results on Thursday, November 13th. The company reported ($0.58) earnings per share for the quarter. The business had revenue of $0.24 million during the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP bought a new stake in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 8,000 shares of the company’s stock, valued at approximately $140,000. Coeptis Therapeutics makes up 0.0% of Yorkville Advisors Global LP’s portfolio, making the stock its 24th largest position. Yorkville Advisors Global LP owned approximately 0.17% of Coeptis Therapeutics as of its most recent SEC filing. 13.88% of the stock is currently owned by institutional investors and hedge funds.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.